Nanjing Vazyme Biotech Résultats passés
Passé contrôle des critères 1/6
Nanjing Vazyme Biotech's earnings have been declining at an average annual rate of -42%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 5.5% per year. Nanjing Vazyme Biotech's return on equity is 0.6%, and it has net margins of 1.7%.
Informations clés
-42.0%
Taux de croissance des bénéfices
-77.6%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 11.3% |
| Taux de croissance des recettes | 5.5% |
| Rendement des fonds propres | 0.6% |
| Marge nette | 1.7% |
| Dernière mise à jour des bénéfices | 30 Sep 2024 |
Mises à jour récentes des performances passées
Recent updates
Ventilation des recettes et des dépenses
Comment Nanjing Vazyme Biotech gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Sep 24 | 1,403 | 24 | 720 | 307 |
| 30 Jun 24 | 1,364 | 26 | 714 | 309 |
| 31 Mar 24 | 1,285 | -15 | 703 | 324 |
| 31 Dec 23 | 1,286 | -71 | 702 | 339 |
| 30 Sep 23 | 2,133 | -232 | 843 | 373 |
| 30 Jun 23 | 2,520 | -101 | 903 | 411 |
| 31 Mar 23 | 2,896 | 112 | 917 | 410 |
| 31 Dec 22 | 3,569 | 594 | 911 | 396 |
| 30 Sep 22 | 2,885 | 878 | 730 | 352 |
| 30 Jun 22 | 2,663 | 900 | 663 | 303 |
| 31 Mar 22 | 2,302 | 773 | 587 | 263 |
| 31 Dec 21 | 1,869 | 678 | 511 | 230 |
| 30 Sep 21 | 1,715 | 767 | 432 | 188 |
| 31 Dec 20 | 1,564 | 822 | 290 | 126 |
| 31 Dec 19 | 268 | 26 | 144 | 62 |
| 31 Dec 18 | 171 | 1 | 93 | 53 |
Des revenus de qualité: 688105 has a large one-off gain of CN¥185.5M impacting its last 12 months of financial results to 30th September, 2024.
Augmentation de la marge bénéficiaire: 688105 became profitable in the past.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 688105's earnings have declined by 42% per year over the past 5 years.
Accélération de la croissance: 688105 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Bénéfices par rapport au secteur d'activité: 688105 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (0.08%).
Rendement des fonds propres
ROE élevé: 688105's Return on Equity (0.6%) is considered low.